Stockscreener 앱 받기
10.52
2.14%
-0.23
시간 외 거래:
10.52
Entrada Therapeutics Inc 주식(TRDA)의 최신 뉴스
Is Entrada Therapeutics Inc. stock safe for conservative investorsQuarterly Investment Review & AI Driven Stock Reports - ulpravda.ru
Is Entrada Therapeutics Inc. stock vulnerable to regulatory risks2026 world cup usa national team group stage goalkeepers transition play winner prediction breakdown - ulpravda.ru
What insider trading reveals about Entrada Therapeutics Inc. stockJuly 2025 Review & Growth Focused Stock Reports - ulpravda.ru
Entrada Therapeutics Highlights Progress Across Its Portfolio of Rna-Based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases - MarketScreener
Entrada Therapeutics highlights RNA pipeline progress and outlook - TipRanks
Entrada reports progress on DMD treatments, shares clinical timeline By Investing.com - Investing.com Australia
Entrada Therapeutics Advances Clinical Pipeline and Reports Progress Amid Upcoming Data Releases and New Ocular Candidate Selection - Quiver Quantitative
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases - GlobeNewswire Inc.
Entrada Therapeutics Reports Increased Losses Amid R&D Expansion - MSN
Price-Driven Insight from (TRDA) for Rule-Based Strategy - Stock Traders Daily
Azenta elects Entrada CEO to Board of Directors - MSN
Vesuvius India Limited Moves Into Overbought Range Analysts CautiousSell Signals and Alerts & Double Or Triple Wealth - bollywoodhelpline.com
Entrada Therapeutics Inc (TRDA) Stock News & Articles - 24/7 Wall St.
AVP Infracon Limited Breaks Below Key Support LevelGlobal Trade Effects & Affordable Trading Strategies - Bollywood Helpline
Analyst Downgrade: Will Entrada Therapeutics Inc stock return to pre crisis levels2025 Market Overview & Verified Entry Point Detection - moha.gov.vn
Tubes Limited Inches Toward Key Resistance — Will It BreakRisk Adjusted Returns & Low Risk Trading Ideas - Bollywood Helpline
Beeyu Overseas Limited Included in Top Momentum ScanVolume Profile Analysis & Big Data Market Reports - Bollywood Helpline
Option Seller’s Risk Unlimited (in theory)REITs Market Trends & Big Gains Small Capital - bollywoodhelpline.com
Entrada Therapeutics, Inc.Common Stock (NQ: TRDA - FinancialContent
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN) - The Globe and Mail
Entrada Therapeutics Earnings Notes - Trefis
How Entrada Therapeutics Inc. stock compares to industry benchmarksDay Trade & Safe Capital Allocation Plans - Улправда
Is Entrada Therapeutics Inc. stock positioned for long term growth2025 Volume Leaders & Fast Momentum Stock Entry Tips - Улправда
How Entrada Therapeutics Inc. stock reacts to job market dataWeekly Trade Review & Risk Controlled Swing Alerts - Улправда
How resilient is Entrada Therapeutics Inc. stock in market downturnsJuly 2025 Snapshot & Weekly High Return Stock Forecasts - DonanımHaber
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st
Will Entrada Therapeutics Inc. stock benefit from commodity pricesWeekly Trading Summary & Verified Technical Signals - DonanımHaber
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Entrada Therapeutics : Corporate Presentation December 2025 - marketscreener.com
5AM Venture Management LLC Has $28.95 Million Stake in Entrada Therapeutics, Inc. $TRDA - MarketBeat
Trading Systems Reacting to (TRDA) Volatility - Stock Traders Daily
Entrada Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Entrada Therapeutics Reports Third Quarter 2025 Financial Results - ADVFN
Brokerages Set Entrada Therapeutics, Inc. (NASDAQ:TRDA) Price Target at $20.67 - Defense World
Baker Bros. Advisors LP Increases Stake in Entrada Therapeutics Inc. - GuruFocus
Major Investment Alert: Baker Bros. Advisors Boosts Stake in Entrada Therapeutics! - TipRanks
Kory James Wentworth Sells 8,910 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - MarketBeat
Insider Sell: Kory Wentworth Sells Shares of Entrada Therapeutics Inc (TRDA) - GuruFocus
Entrada Therapeutics CFO Sells Shares Under Trading Plan - TradingView
CFO Wentworth Sells 8,910 ($88.9K) Of Entrada Therapeutics Inc [TRDA] - TradingView
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
CFO Wentworth Files To Sell 8,910 Of Entrada Therapeutics Inc [TRDA] - TradingView
Will Entrada Therapeutics Inc. stock deliver shareholder valueWeekly Loss Report & Daily Momentum Trading Reports - newser.com
Entrada Therapeutics (TRDA) Price Target Decreased by 10.81% to 16.83 - MSN
Why Entrada Therapeutics Inc. stock is favored by pension fundsTrade Volume Summary & Reliable Volume Spike Trade Alerts - newser.com
(TRDA) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
How risky is Entrada Therapeutics Inc. stock now2025 Year in Review & Real-Time Stock Entry Alerts - newser.com
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells 200,000 Shares of Stock - MarketBeat
0.80%
4.56%
자본화:
|
볼륨(24시간):